Proven leader in building commercial organizations to prepare markets and deliver successful product launches
Planning for the launch of Seladelpar to complete the development and approval applications
NEWARK, Calif., May 10, 2021 (GLOBE NEWSWIRE) – CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need , announced today Veteran Biopharma Manager Lewis Stuart has joined the company as Chief Commercial Officer. Mr. Stuart brings over 25 years of marketing, sales, market access and other commercial roles to successful biotech companies, bringing new therapies to market for womens health, oncology, metabolism and rare diseases.
Mr. Stuart most recently served as Vice President and Prostate Cancer Franchisee for Myovant Sciences. In this role, he led the cross-functional team at Prostate Cancer Launch Readiness across the retail, medical, legal, and manufacturing sectors. Mr. Stuart also led the strategic collaboration with Pfizer, focusing on the joint promotion and life cycle plans of ORGOVYXTM, a new therapy for advanced prostate cancer.
“We are very excited to welcome Lewis to the CymaBay team. His addition marks the beginning of a critical next step in the advancement of Seladelpar for patients with PBC, ”said Sujal Shah, President and Chief Executive Officer of CymaBay. “We are fortunate to have recruited a seasoned biotechnology executive like Lewis who has a proven track record of successfully bringing multiple products to market, including rare disease and women’s health. His skills will be of great importance to CymaBay, and the timing of his team’s pre-commercial efforts will seamlessly affect the expected completion of our recently launched Phase 3 study and subsequent regulatory filings. “
“It is an honor to join the CymaBay team at this crucial time as the company completes its Phase 3 study of Seladelpar and looks towards the potential market launch of the therapy,” said Stuart. “I was drawn to the company because of its focus on patient care, cutting-edge research and scientific integrity and I am very excited to be joining such a talented team.”
Prior to Myovant, Lewis held senior positions at several leading biopharmaceutical companies, including Vice President of Oncology for Genomic Health, a leading provider of genome-based molecular testing; and Chief Commercial Officer for Cardiovascular Focused CV Therapeutics, where he led marketing, commercial operations, medical affairs and a high-performing 250-strong sales team. Other roles included leading the launch of Viracept (nelfinavir), which was becoming the most prescribed protease inhibitor for HIV at the time, and Vice President Global Marketing at Insmed, where he led the launch of mecasermin in Europe and the Middle East for the treatment of Laron’s syndrome, a type of stunted growth. During his career, he has served on the board of directors and trading advisor to several biotech and investment firms, including Linkage Biosciences, Amygdala Neurosciences, and Green House Capital Partners.
About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver disease and other chronic diseases with high unmet medical need through a variety of innovative therapies. Our deep understanding of the mechanisms underlying liver inflammation and fibrosis, as well as the unique goals that play a role in its progression, has helped us win the US Food and Drug Administration’s award for groundbreaking therapy, PRIority MEdicines status (European Medicines Agency) and Orphan to receive drug status (US and Europe) for Seladelpar, a first-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To find out more, visit www.cymabay.com and follow us on Twitter and Linkedin.
Warning notices
All statements made in this press release regarding the potential approval, launch and commercialization of Seladelpar or the schedule or plans relating thereto, as well as statements regarding the completion of ongoing clinical trials and subsequent regulatory filings are forward-looking statements that involve risks and uncertainties. The actual results and timing of events related to the development of Seladelpar may be due to risks and uncertainties, including but not limited to: the success, cost and timing of all of CymaBay’s product development activities, including clinical trials; Effects that have been observed in previous studies and may not be repeated in the future; Delays or inability to obtain or maintain regulatory approval of CymaBay’s product candidates in the United States or worldwide; and the ability of CymaBay to raise sufficient funding to complete the development, regulatory approval and commercialization of its product candidates in the US and worldwide. Additional risks relating to CymaBay are included in CymaBay’s filings with the Securities and Exchange Commission, including, but not limited to, its most recent Annual Report on Form 10-K and other documents later filed with the Securities and Exchange Commission Securities and Exchange Commission have been submitted. CymaBay disclaims any obligation to update these forward-looking statements unless required by law.
PR contact:
Glenn Silver
Lazar-FINN partner
(973) 818-8198
[email protected]
Investor Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
[email protected]
